Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis
Maastricht University · University of California, San Diego · +23 more institutions
Abstract
Neuroimaging studies have shown structural alterations in several brain regions in children and adults with attention deficit hyperactivity disorder (ADHD). Through the formation of the international ENIGMA ADHD Working Group, we aimed to address weaknesses of previous imaging studies and meta-analyses, namely inadequate sample size and methodological heterogeneity. We aimed to investigate whether there are structural differences in children and adults with ADHD compared with those without this diagnosis.
In this cross-sectional mega-analysis, we used the data from the international ENIGMA Working Group collaboration, which in the present analysis was frozen at Feb 8, 2015. Individual sites analysed structural T1-weighted MRI brain scans with harmonised protocols of individuals with ADHD compared with those who do not have this diagnosis. Our primary outcome was to assess case-control differences in subcortical structures and intracranial volume through pooling of all individual data from all cohorts in this collaboration. For this analysis, p values were significant at the false discovery rate corrected threshold of p=0·0156.
Citation impact
- FWCI
- 57.19
- Percentile
- 100%
- References
- 38
Authors
82- MHMartine HoogmanCorresponding
Maastricht University, University of California, San Diego, Otto-von-Guericke University Magdeburg, University Hospital Frankfurt, Nathan Kline Institute for Psychiatric Research, Goethe University Frankfurt
- JBJanita Bralten
University Hospital Frankfurt, University of California, San Diego, Otto-von-Guericke University Magdeburg, Nathan Kline Institute for Psychiatric Research, Maastricht University, Goethe University Frankfurt
- DPDerrek P. Hibar
University of Southern California
- MMMaarten Mennes
Radboud University Nijmegen
- MPMarcel P. Zwiers
Nathan Kline Institute for Psychiatric Research, Radboud University Nijmegen, Otto-von-Guericke University Magdeburg, Goethe University Frankfurt, University Hospital Frankfurt, University of California, San Diego, Maastricht University
Topics & keywords
- Cross-sectional study
- Attention deficit hyperactivity disorder
- Mega-
- Psychology
- Brain size
- Psychiatry
- Clinical psychology
- Medicine
- Partnerships for the goals
Funding
- UDU.S. Department of Defense
- ELEli Lilly and Company
- PPfizer
- MMerck
- NNovartis
- AAAmerican Academy of Child and Adolescent Psychiatry
- MCMcNeil Center for Early American Studies
- OHOregon Health and Science University
- SKStiftelsen Kristian Gerhard Jebsen
- BUBrandeis University
- SSunovion
- HRHealth Research Board
- SAShire Australia
- FRForest Research Institute
- IDInstituto D'Or de Pesquisa e Ensino
- DODepartment of Health and Social Care
- ECEuropean CommissionAwards: 643051, 602450, FP7/2007-2013, 278948, 2007-2013, FP7/2007, 667302, 602805
- DFDeutsche ForschungsgemeinschaftAwards: IRTG1328, RE1632/5–1, RE1632/5-1, SFB-TRR 58/B01, SFB-TRR 58, 602805, TRR 58/A1 and A5, FP7/2007-2013, TRR SFB 58 B06, KFO 125, KFO-112, TRR 58, 667302
- RURadboud Universiteit
- VUVrije Universiteit Amsterdam
- GDGeneralitat de Catalunya
- NONederlandse Organisatie voor Wetenschappelijk OnderzoekAwards: 602805, 453-10-005, 1750102007010, 91.776.384, Vici-453-10-005, 667302, FP7/2007-2013, 433-09-229, 433–09–242, 016-130-669
- AAccare
- MDMinisterio de Economía y CompetitividadAwards: PI12/01139, SAF2012–32362, PI12/, SAF2012
- LLundbeckfonden
- SShire
- SNStavros Niarchos Foundation
- UIUniversitetet i Bergen
- UMUniversitair Medisch Centrum Groningen
- RURadboud Universitair Medisch Centrum
- OPOtsuka Pharmaceutical
- ECEuropean College of Neuropsychopharmacology
- SServier
- HLH. Lundbeck A/S
- NINational Institutes of HealthAwards: R01MH094639, R01MH081803, K23MH087770, T32MH67763, FP7/2007-2013, R01MH083246, EB020403, U01MH099059, R01MH62873, U54 EB020403
- UFU.S. Food and Drug Administration
- H2Horizon 2020 Framework ProgrammeAward: 667302
- SFSeventh Framework ProgrammeAwards: 327340, 602805, 278948, 602450
- MRMedical Research CouncilAward: G03001896
- ARAustralian Research CouncilAward: FT110100548
- NHNational Health and Medical Research CouncilAward: APP1103623
- NINational Institute of Mental HealthAwards: 5R01MH101519, U01 MH109536-01, R01MH62873, RO1 MH62152, U54 EB020403, R21 MH091461
- NINational Institute on Drug AbuseAward: HHSN271200800009C
- JPJanssen Pharmaceuticals
- CCilag